ArticleFrontiers in pediatrics2026
Development and validation of a nomogram for predicting recurrent plastic bronchitis in children with Mycoplasma pneumoniae pneumonia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plastic bronchitis (PB) is a complication of Mycoplasma pneumoniae pneumonia (MPP) in children, characterized by bronchial cast formation and airway obstruction. Recurrence after bronchoscopic cast removal can occur, and tools for early risk prediction are limiting. This study aimed to develop and externally validate a nomogram for predicting recurrent PB in children with MPP after initial bronchoscopic cast removal. Methods: This retrospective multicenter cohort study included pediatric patients with MPP complicated by PB. Patients from one center were randomly divided into a training cohort and an internal validation cohort at a ratio of 8:2, while an independent cohort from another tertiary hospital served as the external validation chort. Candidate predictors were screened using least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable logistic regression to identify independent predictors and develop the prediction model. Model performance was evaluated by discrimination, calibration, and clinical utility using receiver operating characteristic (ROC) curves, calibration plots, the Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA). Results: A total of 352 children with MPP complicated by PB were included, with 281 patients in the training cohort and 71 in the internal validation cohort. An additional 44 patients from an independent center formed the external validation cohort. Four variables were identified as independent predictors of PB recurrence: serum albumin (ALB), fever persisting for ≥72 h after the first bronchoalveolar lavage (BAL), atelectasis, and bronchial casts involving ≥2 lung lobes. These predictors were incorporated into a nomogram. The model showed discrimination across the three cohorts, with an area under curve (AUC) of 0.853 in the training cohort, 0.833 in the internal validation cohort, and 0.811 in the external validation cohort. Calibration plots showed agreement between predicted and observed risks, and decision curve analysis indicated a higher net benefit than the treat-all and treat-none strategies across a range of threshold probabilities. Conclusion: We developed and externally validated a nomogram to predict PB recurrence in children with MPP using routinely available clinical and bronchoscopic variables. The model showed consistent discrimination and calibration. Its potential clinical utility for risk stratification and post-procedural monitoring requires further prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.